Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel El Fassi

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Hematology. American Society of Hematology. Education Program|December 9, 2023
Bispecific antibody therapiesLuiz Henrique de Assis, Daniel El Fassi, Martin Hutchings
European Journal of Endocrinology|April 29, 2006
The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment optionDaniel El Fassi, Claus H Nielsen, Hans C Hasselbalch, et al.
European Journal of Rheumatology|August 27, 2019
Remembering visceral leishmaniasis as a potential trigger of haemophagocytic lymphohistiocytosis in individuals treated with anti-TNF-alpha therapyAmina Nardo-Marino, Katrine Bukan, Henrik Vedel Nielsen, et al.
Thyroid : Official Journal of the American Thyroid Association|August 8, 2006
Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletionDaniel El Fassi, Claus H Nielsen, Hans C Hasselbalch, et al.
Gut|April 15, 2008
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' diseaseDaniel El Fassi, Claus H Nielsen, Jens Kjeldsen, et al.
Expert Opinion on Biological Therapy|August 2, 2007
B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding familyClaus H Nielsen, Daniel El Fassi, Hans C Hasselbalch, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 2007
Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' diseaseDaniel El Fassi, Ole Clemmensen, Claus H Nielsen, et al.
The Journal of Clinical Endocrinology and Metabolism|February 8, 2007
B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot studyDaniel El Fassi, Claus H Nielsen, Steen J Bonnema, et al.
Analytical Biochemistry|May 25, 2021
A user's guide to multicolor flow cytometry panels for comprehensive immune profilingStaffan Holmberg-Thyden, Kirsten Grønbæk, Anne Ortved Gang, et al.
Thyroid : Official Journal of the American Thyroid Association|August 30, 2008
Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trialsJ Paul Banga, Claus H Nielsen, Jacqueline A Gilbert, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Hematology. American Society of Hematology. Education Program|December 9, 2023
Bispecific antibody therapiesLuiz Henrique de Assis, Daniel El Fassi, Martin Hutchings
European Journal of Endocrinology|April 29, 2006
The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment optionDaniel El Fassi, Claus H Nielsen, Hans C Hasselbalch, et al.
European Journal of Rheumatology|August 27, 2019
Remembering visceral leishmaniasis as a potential trigger of haemophagocytic lymphohistiocytosis in individuals treated with anti-TNF-alpha therapyAmina Nardo-Marino, Katrine Bukan, Henrik Vedel Nielsen, et al.
Thyroid : Official Journal of the American Thyroid Association|August 8, 2006
Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletionDaniel El Fassi, Claus H Nielsen, Hans C Hasselbalch, et al.
Gut|April 15, 2008
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' diseaseDaniel El Fassi, Claus H Nielsen, Jens Kjeldsen, et al.
Expert Opinion on Biological Therapy|August 2, 2007
B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding familyClaus H Nielsen, Daniel El Fassi, Hans C Hasselbalch, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 2007
Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' diseaseDaniel El Fassi, Ole Clemmensen, Claus H Nielsen, et al.
The Journal of Clinical Endocrinology and Metabolism|February 8, 2007
B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot studyDaniel El Fassi, Claus H Nielsen, Steen J Bonnema, et al.
Analytical Biochemistry|May 25, 2021
A user's guide to multicolor flow cytometry panels for comprehensive immune profilingStaffan Holmberg-Thyden, Kirsten Grønbæk, Anne Ortved Gang, et al.
Thyroid : Official Journal of the American Thyroid Association|August 30, 2008
Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trialsJ Paul Banga, Claus H Nielsen, Jacqueline A Gilbert, et al.
Pageof 5